AmplifyBio and RNAV8 Bio Form Strategic Partnership for mRNA Therapeutic Development

AmplifyBio and RNAV8 Bio announced a strategic partnership aimed at streamlining the development of mRNA therapeutics, from initial sequence design to Good Manufacturing Practice (GMP) production. AmplifyBio, combining services as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), will collaborate with RNAV8 Bio, a startup specializing in mRNA engineering, to offer comprehensive support for mRNA drug developers.

The partnership seeks to address critical infrastructure gaps that slow the progress of mRNA therapeutics in treating both rare and common diseases. By integrating RNAV8 Bio's advanced mRNA design platforms, which utilize machine learning and artificial intelligence, with AmplifyBio's extensive capabilities in preclinical and clinical manufacturing, the collaboration promises to offer an enhanced, seamless pathway from drug conception to clinic readiness.

J. Kelly Ganjei, CEO of AmplifyBio, highlighted the strategic alignment of their capabilities with RNAV8's tools, emphasizing a unified approach to rapid prototyping, testing, and scale-up in a purpose-built environment. This collaboration aims to equip clients with the necessary framework to develop next-generation mRNA therapeutics more efficiently.